Hepatitis B virus (HBV) is a global public health problem with an estimated number of 350 million carriers world wide who are at risk of development of severe liver disease and hepatocellular carcinoma. Despite currently available nucleoside analogue therapies no general therapeutic breakthrough, which completely clears infection has been achieved after more then two decades of research. Therefore there is a continuing need to identify new antiviral targets that may be translated into useful therapies. / Hepatitis B fusion represents a possible novel antiviral target. However, its mechanism and the envelope proteins involved remain unknown, due to the lack of an efficient infection system to study the early stages of virus infection. On the other hand, the study of the related duck hepatitis B virus (DHBV) and the ability to carry out an in vitro infection of primary duck hepatocytes has provided some insight into the hepadnaviral mechanism of entry and the role of envelope proteins domains in this process. ( For complete abstract open document)
| Identifer | oai:union.ndltd.org:ADTP/245255 |
| Creators | Chojnacki, Jakub |
| Source Sets | Australiasian Digital Theses Program |
| Language | English |
| Detected Language | English |
| Rights | Terms and Conditions: Copyright in works deposited in the University of Melbourne Eprints Repository (UMER) is retained by the copyright owner. The work may not be altered without permission from the copyright owner. Readers may only, download, print, and save electronic copies of whole works for their own personal non-commercial use. Any use that exceeds these limits requires permission from the copyright owner. Attribution is essential when quoting or paraphrasing from these works., Open Access |
Page generated in 0.0022 seconds